Literature DB >> 16966827

Serum hyaluronan concentration as a marker of angiopathy in patients with diabetes mellitus.

Shinichiro Mine1, Yosuke Okada, Chie Kawahara, Takahiro Tabata, Yoshiya Tanaka.   

Abstract

Accumulation of hyaluronan (HA) around smooth muscle cells in lesions of atherosclerosis in diabetic patients suggests that this protein plays an important role in diabetic angiopathy. The aim of this study was to determine the correlation between serum HA concentrations and diabetic angiopathy. Diabetic patients treated with or without an oral hypoglycemic agent and/or insulin for at least 1 year were recruited (n = 95). We also included 20 non-diabetic control subjects. We measured serum levels of HA, body mass index (BMI), fasting plasma glucose (FPG), HbA1c, total cholesterol, triglyceride, glycated albumin (GA), high sensitivity CRP (hs-CRP), monocyte chemoattractant protein (MCP)-1 and evaluated diabetes mellitus history, drug use and presence of related complications. Serum HA levels were significantly (P<0.05) higher in diabetic patients (83.6 +/- 5.6 ng/ml, mean +/- SEM) than in normal subjects (41.7 +/- 12 ng/ml). In diabetic patients, serum HA concentration significantly correlated with FPG, HbA1c, GA, triglyceride and also significantly correlated with BMI, hs-CRP and MCP-1 and tended to be higher in diabetic patients with complications than in those without such complications. Our data suggest that serum HA level correlates with poor blood glucose control and diabetic angiopathy and that it could be used as a marker of diabetic angiopathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966827     DOI: 10.1507/endocrj.k05-119

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  20 in total

Review 1.  Hyaluronan in immune dysregulation and autoimmune diseases.

Authors:  Nadine Nagy; Hedwich F Kuipers; Payton L Marshall; Esther Wang; Gernot Kaber; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-04-04       Impact factor: 11.583

2.  CD44 contributes to hyaluronan-mediated insulin resistance in skeletal muscle of high-fat-fed C57BL/6 mice.

Authors:  Annie Hasib; Chandani K Hennayake; Deanna P Bracy; Aimée R Bugler-Lamb; Louise Lantier; Faisel Khan; Michael L J Ashford; Rory J McCrimmon; David H Wasserman; Li Kang
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-24       Impact factor: 4.310

3.  Hyaluronan levels are increased systemically in human type 2 but not type 1 diabetes independently of glycemic control.

Authors:  Nadine Nagy; Vivekananda G Sunkari; Gernot Kaber; Sonia Hasbun; Dung N Lam; Cate Speake; Srinath Sanda; Tracey L McLaughlin; Thomas N Wight; Steven R Long; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-09-06       Impact factor: 11.583

4.  Cardiovascular Risk and Serum Hyaluronic Acid: A Preliminary Study in a Healthy Population of Low/Intermediate Risk.

Authors:  Chrysanthi Papanastasopoulou; Maria Papastamataki; Petros Karampatsis; Eleni Anagnostopoulou; Ioannis Papassotiriou; Nikolaos Sitaras
Journal:  J Clin Lab Anal       Date:  2016-06-16       Impact factor: 2.352

5.  NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.

Authors:  Aleksandr E Vendrov; Nageswara R Madamanchi; Xi-Lin Niu; Kimberly C Molnar; Mason Runge; Cédric Szyndralewiez; Patrick Page; Marschall S Runge
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

Review 6.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

7.  Low molecular weight hyaluronan activates cytosolic phospholipase A2α and eicosanoid production in monocytes and macrophages.

Authors:  Milena Sokolowska; Li-Yuan Chen; Michael Eberlein; Asuncion Martinez-Anton; Yueqin Liu; Sara Alsaaty; Hai-Yan Qi; Carolea Logun; Maureen Horton; James H Shelhamer
Journal:  J Biol Chem       Date:  2013-12-23       Impact factor: 5.157

Review 8.  Hyaluronan: A Mediator of Islet Dysfunction and Destruction in Diabetes?

Authors:  Rebecca L Hull; Marika Bogdani; Nadine Nagy; Pamela Y Johnson; Thomas N Wight
Journal:  J Histochem Cytochem       Date:  2015-08       Impact factor: 2.479

9.  Hyaluronan synthase 1 (HAS1) requires higher cellular UDP-GlcNAc concentration than HAS2 and HAS3.

Authors:  Kirsi Rilla; Sanna Oikari; Tiina A Jokela; Juha M T Hyttinen; Riikka Kärnä; Raija H Tammi; Markku I Tammi
Journal:  J Biol Chem       Date:  2013-01-09       Impact factor: 5.157

Review 10.  Hyaluronan as a therapeutic target in human diseases.

Authors:  Jiurong Liang; Dianhua Jiang; Paul W Noble
Journal:  Adv Drug Deliv Rev       Date:  2015-11-02       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.